Rachel E Crossland

Dr. Rachel E Crossland

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2017 in Haematologica
Verified
Journal Article
Open access
PDF file
RNRichard A. Noble
Richard A. Noble
NBNatalie Bell
Natalie Bell
HBHelen Blair
Helen Blair
ASArti Sikka
Arti Sikka
HTHuw Thomas
Huw Thomas
SWStephen R. Wedge
Stephen R. Wedge
Inhibition of monocarboxylate transporter 1 has been proposed as a therapeutic approach to perturb lactate shuttling in tumor cells that lack monocarboxylate transporter 4. We examined the monocarboxylate transporter 1 inhibitor AZD3965, currently in phase I clinical studies, as a potential therapy for diffuse large B-cell lymphoma and Burkitt lymphoma. Whilst extensive monocarboxylate transporter 1 protein was found in 120 diffuse large B-cell lymphoma and 10 Burkitt lymphoma patients’ tumors, monocarboxylate transporter 4 protein expression was undetectable in 73% of the diffuse large B-cell lymphoma samples and undetectable or negligible in each Burkitt lymphoma sample. AZD3965 treatment led to a rapid accumulation of intracellular lactate in a panel of lymphoma cell lines with low monocarboxylate transporter 4 protein expression and potently inhibited their proliferation. Metabolic changes induced by AZD3965 in lymphoma cells were consistent with a feedback inhibition of glycolysis. A profound cytostatic response was also observed in vivo: daily oral AZD3965 treatment for 24 days inhibited CA46 Burkitt lymphoma growth by 99%. Continuous exposure of CA46 cells to AZD3965 for 7 weeks in vitro resulted in a greater dependency upon oxidative phosphorylation. Combining AZD3965 with an inhibitor of mitochondrial complex I (central to oxidative phosphorylation) induced significant lymphoma cell death in vitro and reduced CA46 disease burden in vivo. These data support clinical examination of AZD3965 in Burkitt lymphoma and diffuse large B-cell lymphoma patients with low tumor monocarboxylate transporter 4 expression and highlight the potential of combination strategies to optimally target the metabolic phenotype of tumors.

1 February 2016 in Journal of Immunological Methods
Verified
Journal Article
Closed access
Rachel E CrosslandRachel E Crossland
Rachel E Crossland
JNJean Norden
Jean Norden
LBLouis A. Bibby
Louis A. Bibby
JDJoanna Davis
Joanna Davis
ADAnne M. Dickinson
Anne M. Dickinson

24 March 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
Rachel E CrosslandRachel E Crossland
Rachel E Crossland
JNJean Norden
Jean Norden
MJMateja Kralj Juric
Mateja Kralj Juric
KGKile Green
Kile Green
KPKim F. Pearce
Kim F. Pearce
ADAnne M. Dickinson
Anne M. Dickinson
Acute graft versus host disease (aGvHD) is the most frequent and serious complication following haematopoietic stem cell transplantation (HSCT), with a high mortality rate. A clearer understanding of the molecular pathogenesis may allow for improved therapeutic options or guide personalised prophylactic protocols. Circulating microRNAs are expressed in body fluids and have recently been associated with the etiology of aGvHD, but global expression profiling in a HSCT setting is lacking. This study profiled expression of n=799 mature microRNAs in patient serum, using the NanoString platform, to identify microRNAs that showed altered expression at aGvHD diagnosis. Selected microRNAs (n=10) were replicated in independent cohorts of serum samples taken at aGvHD diagnosis (n=42) and prior to disease onset (day 14 post-HSCT, n=47) to assess their prognostic potential. Sera from patients without aGvHD were used as controls. Differential microRNAs were investigated in silico for predicted networks and mRNA targets. Expression analysis identified 61 microRNAs that were differentially expressed at aGvHD diagnosis. MiR-146a (p=0.03), miR-30b-5p (p=0.007), miR-374-5p (p=0.02), miR-181a (p=0.03), miR-20a (p=0.03) and miR-15a (p=0.03) were significantly verified in an independent cohort (n=42). MiR-146a (p=0.01), miR-20a (p=0.03), miR-18 (p=0.03), miR-19a (p=003), miR-19b (0.02) and miR-451 (p=0.01) were differentially expressed 14 days post-HSCT in patients who later developed aGvHD (n=47). High miR-19b expression was associated with improved overall survival (OS) (p=0.008), while high miR-20a and miR-30b-5p were associated with lower rates of non-relapse mortality (p=0.05 and p=0.008) and improved OS (p=0.016 and p=0.021). Pathway analysis associated the candidate microRNAs with haematological and inflammatory disease. Circulating biofluid microRNAs show altered expression at aGvHD onset and have the capacity to act as prognostic and diagnostic biomarkers. Their differential expression in serum suggests a role for circulatory microRNAs in aGvHD pathology, which warrants further investigation.

10 November 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
Rachel E CrosslandRachel E Crossland
Rachel E Crossland
JNJean Norden
Jean Norden
MJMateja Kralj Juric
Mateja Kralj Juric
KPKim F. Pearce
Kim F. Pearce
CLClare Lendrem
Clare Lendrem
ADAnne M. Dickinson
Anne M. Dickinson
Acute graft-versus-host disease (aGvHD) is a major cause of adverse outcome in hematopoietic stem cell transplantation (HSCT), with a high incidence (20-50%). A novel, non-invasive diagnostic test to predict for prevalence and severity would enable improved prophylaxis and reduce morbidity. Circulatory microRNAs miR-423, miR-199, miR-93* and miR-377 have previously been associated with aGvHD in post-HSCT patient plasma, but validation is lacking and their expression within extracellular vesicles (EVs) has not been explored. This study replicated elevated serum expression of miR-423 (p<0.001), miR-199 (p=0.04), miR-93* (p<0.001) and miR-377 (p=0.03) in aGvHD, using a prognostic cohort of day 14 (D14) post-HSCT patient samples (n=81). Expression also associated with disease severity. Further analysis at aGvHD diagnosis in an independent cohort (n=65) confirmed high miR-423 (p=0.02), miR-199 (p=0.007) and miR-93* (p=0.004) expression at disease onset. Investigation of expression patterns during early HSCT sequential timepoints (pre-HSCT to D28) identified elevated microRNAs at D7 post-HSCT in all transplant patients. In a novel investigation of microRNA expression in serum EVs (n=15), miR-423 (p=0.09), miR-199 (p=0.008) and miR-93* (p=0.001) levels were lower at D14 in patients who later developed aGvHD, and this was replicated for miR-423 (p=0.02) and miR-199 (p=0.04) (n=47). Comparing serum to circulating EVs, at D14 patients remaining aGvHD-free had higher expression of miR-423 (p=0.03), miR-199 (p<0.001) and miR-93* (p=0.001) in the EV fraction. Results verify the capacity for circulating miR-423, miR-199 and miR-93* as diagnostic and prognostic aGvHD biomarkers. The novel finding of their differential expression in EVs suggests a potential role in aGvHD etiology.

1 October 2013 in Histopathology
Verified
Journal Article
Closed access
PDF file
Rachel E CrosslandRachel E Crossland
Rachel E Crossland
MSMichal Sieniawski
Michal Sieniawski
BABrian Angus
Brian Angus
GMGeetha K Menon
Geetha K Menon
SPStephen J Proctor
Stephen J Proctor
TMTryfonia Mainou‐Fowler
Tryfonia Mainou‐Fowler

28 January 2023 in Journal of Extracellular Biology
Verified
Journal Article
Open access
Rachel E CrosslandRachel E Crossland
Rachel E Crossland
AAAnna Albiero
Anna Albiero
CSCLARA SANJURJO-RODRÍGUEZ
CLARA SANJURJO-RODRÍGUEZ
MRMonica Reis
Monica Reis
ARAnastasia Resteu
Anastasia Resteu
XWXiao‐Nong Wang
Xiao‐Nong Wang
Extracellular vesicles (EV) and the microRNAs that they contain are increasingly recognised as a rich source of informative biomarkers, reflecting pathological processes and fundamental biological pathways and responses. Their presence in biofluids makes them particularly attractive for biomarker identification. However, a frequent caveat in relation to clinical studies is low abundance of EV RNA content. In this study, we used NanoString nCounter technology to assess the microRNA profiles of n = 64 EV low concentration RNA samples (180–49125 pg), isolated from serum and cell culture media using precipitation reagent or sequential ultracentrifugation. Data was subjected to robust quality control parameters based on three levels of limit of detection stringency, and differential microRNA expression analysis was performed between biological subgroups. We report that RNA concentrations > 100 times lower than the current NanoString recommendations can be successfully profiled using nCounter microRNA assays, demonstrating acceptable output ranges for imaging parameters, binding density, positive/negative controls, ligation controls and normalisation quality control. Furthermore, despite low levels of input RNA, high‐level differential expression analysis between biological subgroups identified microRNAs of biological relevance. Our results demonstrate that NanoString nCounter technology offers a sensitive approach for the detection and profiling of low abundance EV‐derived microRNA, and may provide a solution for research studies that focus on limited sample material.